The beliefs, knowledge, and understanding that adolescents have regarding the function, purpose, and benefits of pursuing an undergraduate degree have always been shaped by the historical, social, political, economic, and even geographical context in which they live. Unfortunately, these constructs do not evolve quickly enough to keep pace with each rapidly changing environment, resulting in a disconnect between their understanding of the subject and their current reality in the workplace, society, and professions. This situation has led to a misconception, both socially and especially among adolescents, that the benefits will arise almost spontaneously or by decree. The truth, in this case, is an amorphous, complex, hidden, and even painful dimension for many adolescents who lack the necessary skills to understand it and act accordingly. Instead of success, this often leads to partial or total failure in their studies and training, ultimately resulting in underemployment or unemployment.

This paper reviews systemic sclerosis (SSc; scleroderma) with emphasis on vasculopathy (digital ischaemia/ulceration and macrovascular disease) and interstitial lung disease (SSc‑ILD), and applies evidence to a 34‑year‑old woman with: bilateral distal upper‑limb arterial thrombosis (radial/ulnar), distal lower‑limb arterial compromise, HRCT chest showing ILD with UIP features plus superadded pneumonitis, very high CRP, prior severe microcytic anaemia now improved, hyponatraemia, vitamin D deficiency, mild TSH elevation, and preserved renal function (case data as provided).

Key points for treating teams: - SSc can plausibly unify (a) severe peripheral ischaemia/digital tissue threat via SSc vasculopathy spanning micro‑ and macrovascular beds and (b) fibrotic ILD, including honeycombing/UIP‑like features in advanced disease; however, the extent of bilateral radial/ulnar thrombosis is atypical and mandates urgent evaluation for overlap/alternative drivers such as antiphospholipid syndrome (APS) or ANCA‑associated vasculitis [1].

- Superadded infection is strongly suggested by very high CRP and CT consolidation; this must be treated promptly before escalation of immunosuppression for ILD, with microbiology and oxygenation assessment [2].

- Evidence‑based therapies for SSc‑ILD centre on mycophenolate (strong recommendation), with options that include cyclophosphamide, rituximab, tocilizumab, nintedanib, and combinations in selected settings (ATS/EULAR/BSR guidance) [3].

- Digital critical ischaemia/tissue necrosis is an emergency; contemporary guidance supports prompt specialist assessment, fast vascular imaging (CTA), vasodilator escalation (PDE5 inhibitors/IV prostanoids), targeted wound/infection care, and a parallel prothrombotic work‑up (APS/ANCA) to decide on antithrombotic and immunomodulatory strategy [4].

Abstract. Systemic sclerosis is a multisystem autoimmune disease characterised by immune dysregulation, vasculopathy, and progressive fibrosis affecting skin and internal organs. Contemporary guidelines highlight a “vascular therapeutic continuum” linking Raynaud’s phenomenon, digital ulcers, and pulmonary arterial hypertension, with parallel antifibrotic/immunomodulatory strategies for SSc‑ILD. This paper synthesises key evidence (EULAR, ATS, ACR/CHEST, BSR, ESC/ERS) and applies it to a young woman with severe peripheral arterial thrombosis and UIP‑like ILD plus pneumonitis. We outline mechanistic plausibility for SSc, critical differentials (ANCA vasculitis, APS, thromboangiitis obliterans), and provide prioritised investigations and a stepwise management algorithm suitable for urgent multidisciplinary care [5].

Background, epidemiology, and risk factors

Introduction. Systemic sclerosis (SSc) is a chronic connective‑tissue disease in which vascular injury and immune activation lead to fibroblast activation and organ fibrosis; major morbidity and mortality arise from ILD and pulmonary hypertension, while peripheral vasculopathy causes Raynaud’s phenomenon, digital ulcers, and occasionally gangrene [6].

Epidemiology (global and Indian context). SSc is rare, shows a strong female predominance, and typically presents in early‑to‑mid adulthood [7]. In Indian cohorts, several series report younger age of onset and a high prevalence of anti‑topoisomerase I (Scl‑70) positivity, with high ILD burden and substantial functional restriction on spirometry—features highly relevant to the current case phenotype [8].

Risk factors. SSc arises from genetic susceptibility interacting with environmental and immunologic triggers. Major environmental associations include crystalline silica exposure and organic solvents, supported by observational evidence and meta‑analyses; these are particularly relevant to occupational histories and should be elicited in India where exposures may be under‑recognised [9].

Pathogenesis and pathology

SSc pathogenesis is best conceptualised as an interlinked triad of autoimmunity, vasculopathy, and fibrosis, beginning with endothelial injury and culminating in persistent myofibroblast activity and extracellular matrix accumulation [10].

Immunologic mechanisms. Innate and adaptive immune activation in SSc includes altered dendritic‑cell and macrophage polarisation, T‑cell dysregulation, and B‑cell activation with production of disease‑associated autoantibodies (e.g., anti‑topoisomerase I, anticentromere, anti‑RNA polymerase III) that correlate with organ phenotypes and prognosis. Cytokine pathways (including IL‑6) and interferon‑related signatures contribute to inflammatory amplification and fibrotic signalling [11].

Vascular mechanisms (micro‑ and macrovascular). Endothelial dysfunction drives vasospasm, impaired angiogenesis/vasculogenesis, capillary dropout, and luminal remodelling. Clinically, this manifests as Raynaud’s phenomenon and digital ulcers; pathobiologically, the same continuum is linked to pulmonary arterial hypertension. [12] Importantly for this patient, SSc is not confined to microvasculature: macrovascular involvement (e.g., ulnar/radial disease, palmar arch compromise, and lower‑extremity arterial disease) has been described, and can contribute to severe digital ischaemic loss [13].

Fibrotic mechanisms. Fibrosis results from sustained activation of fibroblasts/myofibroblasts via profibrotic mediators (classically including TGF‑β‑centred signalling), aberrant mechanotransduction, and persistent inflammatory cues. Organ‑specific modifying factors (e.g., microaspiration in lung, neuro‑motility changes in gut) shape phenotype and progression [14].

Clinical spectrum and systemic manifestations

SSc is clinically heterogeneous; typical phenotyping includes limited cutaneous and diffuse cutaneous disease, but visceral involvement can occur across subsets. Organ complications should be anticipated and actively screened, given that outcomes improve with earlier detection and treatment [15].

Digital ischaemia, ulcers, and macrovascular disease. Raynaud’s phenomenon is often earliest; progression includes recurrent digital ulcers, infection, osteomyelitis, and tissue 

loss. Contemporary guidance frames these as a vascular continuum amenable to vasodilator escalation (CCB → PDE5 inhibitor → IV prostanoid) and—when recurrent ulcers occur—endothelin receptor antagonism (bosentan) to reduce new ulcer formation [16]. Macrovascular stenosis/occlusion can be present in severe cases and may coexist with additional thrombotic drivers (e.g., antiphospholipid antibodies, ANCA positivity, smoking) [17].

Interstitial lung disease. ILD is common in SSc; HRCT may show NSIP most frequently among CTD‑ILD, but UIP‑like fibrosis and honeycombing occur, particularly in advanced disease and specific cohorts [18]. ILD is a leading cause of SSc‑related morbidity/mortality and requires structured screening/monitoring with HRCT and pulmonary function tests (including DLCO) [19].

Pulmonary hypertension. SSc‑associated pulmonary arterial hypertension (SSc‑PAH) is a major determinant of prognosis. Annual screening strategies use symptoms/signs, echocardiography, natriuretic peptides, and pulmonary function metrics; high‑risk algorithms (e.g., DETECT) reduce missed diagnoses and can detect milder disease [20].

Renal involvement. Scleroderma renal crisis (SRC) is a feared complication; risk increases with diffuse disease, anti‑RNA polymerase III positivity, and glucocorticoid exposure. Management relies on immediate ACE inhibitor therapy and cautious steroid use [21]. The provided case has preserved renal function; this does not exclude SSc, but reduces the likelihood of current SRC [22].

Gastrointestinal and nutrition. GI involvement is frequent (reflux, dysmotility, malabsorption). Vascular GI lesions such as gastric antral vascular ectasia (GAVE) can cause chronic blood loss and iron‑deficiency anaemia—important in this case given prior severe microcytic anaemia [23].

Cardiac disease. Primary myocardial involvement (inflammation/fibrosis), arrhythmias, and right‑heart strain from PAH can occur; annual screening (ECG, echo, NT‑proBNP) is recommended in contemporary guidance [22].

Diagnosis and classification

Diagnosis relies on pattern recognition across clinical features, serology, and organ assessment, while classification criteria support standardisation for research and structured clinical thinking.

Core clinical evaluation. History should capture Raynaud’s phenomenon, digital ulceration/gangrene, skin thickening, puffy fingers, inflammatory arthritis/myositis symptoms, reflux/dysphagia, dyspnoea/cough, syncope/exertional limitation, and exposures (silica/solvents) and smoking [24]. Physical examination should assess skin score, sclerodactyly, telangiectasia, calcinosis, tendon friction rub, digital perfusion (capillary refill, temperature), and cardiopulmonary signs.

Serology. ANA by immunofluorescence is a sensitive entry test; ENA should include anti‑topoisomerase I (Scl‑70), anticentromere, and anti‑RNA polymerase III given phenotype correlations (ILD, PAH, SRC) [25]. In the present case, serology is crucial because the vascular phenotype (large‑artery thrombosis) may reflect SSc overlap with APS or vasculitis.

Nailfold capillaroscopy. Detection of a “scleroderma pattern” microangiopathy supports early diagnosis and is integrated into modern criteria/diagnostic algorithms; it is relatively low‑cost and can be implemented widely with training [26].

Imaging and organ testing. - HRCT chest + PFTs (spirometry, lung volumes, DLCO): recommended for screening and longitudinal monitoring of SSc‑ILD; surgical lung biopsy is strongly discouraged for screening/monitoring in SARD‑ILD guidance [19].

- Echocardiography + NT‑proBNP: annual screening for PAH is recommended; right‑heart catheterisation confirms diagnosis [27].

- Vascular imaging: Duplex and, when tissue is threatened or macrovascular disease is suspected, CT angiography guides urgent decisions (revascularisation, thrombolysis, medical escalation). Macrovascular occlusion of ulnar/radial arteries is recognised in severe SSc but remains uncommon enough that alternate causes must be excluded [28].

ACR/EULAR classification criteria. The 2013 ACR/EULAR criteria use a weighted score; a total score ≥9 classifies “definite SSc.” Items include skin thickening (high weight), fingertip lesions, telangiectasia, abnormal nailfold capillaries, PAH/ILD, Raynaud’s phenomenon, and SSc‑specific autoantibodies [29].

Treatment principles and evidence‑based therapies

Modern management is organ‑based, severity‑stratified, and multidisciplinary, balancing infection risk, vascular risk, and progression risk.

Digital ischaemia and ulcer disease (acute and chronic). The European Alliance of Associations for Rheumatology [30] (EULAR) recommends dihydropyridine calcium‑channel blockers (often nifedipine) first line for SSc‑Raynaud; PDE5 inhibitors should be considered; and IV iloprost should be considered for severe Raynaud refractory to oral therapy. For digital ulcers, PDE5 inhibitors and/or IV iloprost are recommended options, and bosentan should be considered to reduce new ulcers (prevention more than healing). [31] The British Society for Rheumatology [32] highlights that new tissue necrosis/critical digital ischaemia is an emergency and supports urgent assessment, PDE5 inhibitors as frontline for healing/secondary prevention, IV prostanoids when needed, and specialist wound care; it also supports antiplatelet therapy consideration in necrotic DU disease [22].

SSc‑ILD immunomodulation and antifibrotics. The American Thoracic Society [33] guideline for SSc‑ILD recommends mycophenolate (strong recommendation) and suggests cyclophosphamide, rituximab, tocilizumab, nintedanib, and nintedanib+mycophenolate in appropriate contexts [34]. EULAR similarly recommends MMF/cyclophosphamide/rituximab for SSc‑ILD, considers nintedanib alone or with MMF, and considers tocilizumab [35]. Landmark trials underpin these choices: cyclophosphamide showed modest benefit vs placebo (SLS‑I), MMF and cyclophosphamide improved outcomes with better tolerability for MMF (SLS‑II), and nintedanib reduced FVC decline (SENSCIS). [36] Tocilizumab preserved FVC in early inflammatory SSc with ILD signals in trial analyses, aligning with guideline positioning in select patients (especially with raised acute‑phase reactants) [37].

Anticoagulation and APS considerations. Routine anticoagulation is not a standard treatment for uncomplicated SSc vasculopathy and is explicitly discouraged in some SSc‑PAH contexts (e.g., warfarin not recommended for SSc‑PAH in EULAR/BSR guidance) [38]. However, this patient’s documented arterial thrombosis (radial/ulnar) justifies an APS work‑up and vascular‑team decisions on antithrombotic therapy as per acute arterial thrombosis protocols (separate from SSc vasodilator strategies). Evidence indicates antiphospholipid antibodies occur in a subset of SSc and may associate with macrovascular disease and outcomes, supporting combined evaluation rather than assuming “pure” SSc vasculopathy [39].

Infection and supportive care. In SSc‑ILD management frameworks, infection control and supportive therapies (pulmonary rehabilitation, nutrition, reflux management, oxygen when hypoxaemic, vaccination) are integral; guidance also advises reducing/stopping immunosuppression in severe fibrosis with recurrent infections and considering antifibrotic‑only approaches in selected high‑infection‑risk scenarios [2].

Managing anaemia, hyponatraemia, vitamin D, thyroid. - Severe microcytic anaemia warrants iron studies and GI evaluation (including consideration of GAVE in SSc), with correction and source control [40].

- Hyponatraemia should be approached systematically (confirm hypotonicity, assess volume status, consider SIADH with pneumonia, correct safely under protocol) [41].

- Vitamin D deficiency is common in India; Indian consensus guidance supports structured replacement strategies based on 25‑OH vitamin D thresholds and risk profile [42].

- Mild TSH elevation requires correlation with free T4 and symptoms; Indian consensus guidance outlines when to treat vs monitor in subclinical hypothyroidism [43].

Prognosis and outcomes (high‑level). Prognosis hinges on cardiopulmonary involvement (ILD/PAH), the rate of physiologic decline, and extent of fibrosis; guideline‑driven screening and earlier treatment are associated with better outcomes in contemporary cohorts [44].

Prevention strategies. Preventive care in SSc is primarily secondary prevention: early identification, regular organ screening (ILD/PAH/cardiac/renal), cold protection and smoking cessation to reduce vascular events, vaccination and infection prevention during immunosuppression, reflux management to reduce microaspiration‑related lung injury, and occupational risk mitigation (silica/solvents) when relevant [45].

Case discussion and recommended pathway for the provided patient

Case synthesis: how SSc could explain the pattern (and what is atypical)

What fits SSc well - ILD with UIP‑like features (honeycombing/traction bronchiectasis) is compatible with advanced fibrotic CTD‑ILD; SSc‑ILD is common and a leading driver of morbidity, and guidelines prioritise HRCT+PFT‑based pathways and early therapy for progressive disease [46].

- Severe peripheral ischaemia is part of the SSc vascular continuum; macrovascular disease (including ulnar/radial/palmar arch) has been described and can contribute to severe tissue loss [47].

What is atypical / red‑flag for overlap - Bilateral radial and ulnar arterial thrombosis (upper limbs) plus distal lower‑limb compromise suggests either unusually aggressive macrovascular SSc vasculopathy or an additional systemic prothrombotic/inflammatory vasculitic driver. In SSc, co‑positivity for aPL or ANCA and smoking can associate with digital gangrene and macrovascular stenosis; therefore, “SSc alone” should not be assumed [17].

- Very high CRP with CT consolidation suggests superadded infection, which may both worsen vascular events (inflammation‑thrombosis coupling) and contraindicate immediate immunosuppression escalation until controlled [2].

Other case elements that may connect - Prior severe microcytic anaemia could reflect iron deficiency from nutritional causes or chronic blood loss; in SSc specifically, GAVE is a recognised cause of iron‑deficiency anaemia and should be actively considered if GI symptoms/occult blood loss are present [48].

Differential diagnosis comparison table

Recommended investigations with priority, rationale, and timing

Treatment algorithm for digital ischaemia in suspected SSc (adaptable to local protocols)

Stepwise management plan for this patient (pragmatic and team‑ready)

Immediate priorities (today) 1. Treat limb threat as a vascular emergency: urgent vascular consult, limb staging, pain control, and CTA upper/lower limbs to define occlusion anatomy and intervention options [49].

2. Treat likely superadded pneumonitis: obtain cultures and start empiric antibiotics per local policy, with oxygenation assessment (SpO₂ trend/ABG). Delay escalation of immunosuppression until infection is stabilised unless a competing life‑threatening immune process is proven [2].

3. Launch parallel aetiology work‑up: ANA/ENA, ANCA, APS panel, coagulation profile/D‑dimer, urinalysis/protein, echocardiography/NT‑proBNP, baseline PFTs when feasible [51].

Near‑term priorities (next 48–72 hours) - Start/optimise vasodilator strategy for severe peripheral ischaemia (CCB → PDE5 inhibitor; consider IV prostanoid in refractory/critical cases) with blood pressure monitoring and haemodynamic caution [50].

- Once infection is controlled and phenotype clarified, initiate an SSc‑ILD plan (often MMF as first‑line), with consideration of tocilizumab/rituximab/nintedanib depending on inflammatory profile, fibrosis extent, and infection risk [52].

- Evaluate anaemia: iron studies and occult blood loss; consider GI evaluation for GAVE if unexplained iron deficiency persists [48].

Supportive/metabolic corrections - Hyponatraemia: confirm type and correct safely under guideline‑based protocols, especially if pneumonia‑associated SIADH is suspected [41].

- Vitamin D deficiency: treat per Indian consensus recommendations (dose and schedule per local endocrinology/medicine protocol) [42].

- Mild TSH elevation: check free T4 and thyroid peroxidase antibodies; follow Indian consensus on when to treat vs observe in subclinical hypothyroidism [43].